Clinical Trial Update: Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan [Phase 3]

View source ↗

Summary

Pfizer-sponsored Phase 3 trial evaluating Linezolid for nosocomial infections caused by methicillin-resistant Staphylococcus aureus in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methicillin-resistant Staphylococcus Aureus Infections
• Nosocomial Infections

Drugs mentioned

• Linezolid (Zyvox) (linezolid)

Snippet

Sponsor: Pfizer | Conditions: Infections, Nosocomial | Phase 3 | Status: COMPLETED